VIDEO: Macular neovascularization did not impact reduction in GA growth in GATHER trials
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.
The phase 3 GATHER1 and GATHER2 clinical trials examined the use of avacincaptad pegol in patients with geographic atrophy. Grewal said he and colleagues observed a slight increase in the incidence of macular neovascularization in patients treated with avacincaptad pegol (11.6%) vs. patients in the sham group (6.9%) in pooled data from both trials.
“Overall, our analysis found that development of macular neovascularization did not impact the reduction in GA growth, and outcomes of vision were similar at 18 months in eyes whether they developed macular neovascularization following the study drug or as an actual history of their macular degeneration,” Grewal said.
Collapse
Grewal D. Characterization of eyes with geographic atrophy that developed macular neovascularization in the GATHER clinical trials. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts